European Urology Oncology

Slides:



Advertisements
Similar presentations
Volume 71, Issue 5, Pages (May 2017)
Advertisements

Volume 60, Issue 5, Pages (November 2011)
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,
Volume 68, Issue 6, Pages (December 2015)
Volume 58, Issue 4, Pages (October 2010)
European Urology Focus
Volume 70, Issue 6, Pages (December 2016)
Volume 72, Issue 1, Pages (July 2017)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
European Urology Oncology
Volume 69, Issue 1, Pages (January 2016)
Volume 51, Issue 4, Pages (April 2007)
European Urology Oncology
Volume 70, Issue 4, Pages (October 2016)
Volume 62, Issue 1, Pages (July 2012)
Volume 68, Issue 4, Pages (October 2015)
Volume 67, Issue 2, Pages (February 2015)
Volume 67, Issue 2, Pages (February 2015)
European Urology Oncology
Next-generation Sequencing of Urologic Cancers: Next Is Now
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma  Francesco Gatto, Kyle A. Blum, Seyedeh Shaghayegh.
Volume 71, Issue 6, Pages (June 2017)
Laurent Boccon-Gibod  European Urology Supplements 
Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E
Volume 70, Issue 2, Pages (August 2016)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 66, Issue 2, Pages (August 2014)
Volume 63, Issue 3, Pages (March 2013)
Volume 72, Issue 4, Pages (October 2017)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
European Urology Oncology
Volume 71, Issue 6, Pages (June 2017)
Volume 71, Issue 5, Pages (May 2017)
European Urology Oncology
Volume 49, Issue 4, Pages (April 2006)
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Volume 70, Issue 6, Pages (December 2016)
Long-Term Hormonal Therapy: Who Would Benefit?
Volume 74, Issue 3, Pages (September 2018)
European Urology Oncology
Volume 70, Issue 1, Pages (July 2016)
Volume 75, Issue 3, Pages (March 2019)
European Urology Oncology
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder  Devin N. Patel, Michael Luu, Zachary.
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review  Alexey Surov, Hans Jonas Meyer, Andreas.
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis  Joseph Sargon Joseph, Vincent.
Axel Heidenreich  European Urology Supplements 
European Urology Oncology
Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi- Institutional Retrospective Study Using a Propensity Score Analysis 
Oncoforum Urology: Prostate Cancer 2008 at a Glance
European Urology Oncology
Axel Heidenreich  European Urology Supplements 
European Urology Oncology
(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.
European Urology Oncology
Disease-Free Interval Length Correlates to Prognosis of Patients Who Underwent Metastasectomy for Esophageal Lung Metastases  Satoshi Shiono, MD, Masafumi.
Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.
European Urology Oncology
Fig. 2. HR estimated by the multivariate analysis for predicting factors associated with longer overall survival using a Cox regression model at the time.
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Presentation transcript:

European Urology Oncology Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer  Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, Shintaro Narita, Masahiro Takahashi, Koji Mitsuzuka, Shingo Hatakeyama, Toshihiko Sakurai, Sadafumi Kawamura, Shigeto Ishidoya, Senji Hoshi, Masanori Ishida, Kei Mizuno, Keiji Ogura, Takayuki Goto, Naoki Terada, Takashi Kobayashi, Toshinari Yamasaki, Takahiro Inoue, Norihiko Tsuchiya, Chikara Ohyama, Yoichi Arai, Tomonori Habuchi, Satoshi Morita, Osamu Ogawa  European Urology Oncology  DOI: 10.1016/j.euo.2018.10.011 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Risk stratification based on the distribution of predicted hazard ratios. Each combination of risk factors (x-axis) was scored according to regression coefficients for the multivariable Cox model (Table 3). The y-axis shows the hazard ratio calculated for each combination. We defined three risk groups according to the risk scores: 0=low; <1.5=intermediate; and >1.5=high. GS=Gleason score; LDH=lactate dehydrogenase; EOD=extent of disease. European Urology Oncology DOI: (10.1016/j.euo.2018.10.011) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Overall survival stratified according to the novel prognostic model. Results are shown for (A) cases diagnosed in 2002 or later and (B) all patients in the discovery cohort. CI=confidence interval; NE=not estimable. European Urology Oncology DOI: (10.1016/j.euo.2018.10.011) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Overall survival for the validation cohort stratified according to the novel prognostic model. CI=confidence interval; NE=not estimable. European Urology Oncology DOI: (10.1016/j.euo.2018.10.011) Copyright © 2018 European Association of Urology Terms and Conditions